Archive · 6 Jan 2026
Indian Drug Innovation Bets Pay Off
Wockhardt, an Indian company, has been working on making new antibiotics for over 20 years.
In 2025, they launched a new antibiotic called Miqnaf in India.
Another antibiotic, Zaynich, was accepted by the US FDA, which is a big deal because it's the first new antibiotic from India to get this approval.
Wockhardt is planning to launch Zaynich in the US in mid-2026.
This shows that India is making progress in creating new medicines.
Wockhardt has been working on antibiotic drug discovery for over two decades.
Miqnaf, an antibiotic, was launched in India in 2025.
Zaynich, another antibiotic, became the first Indian new chemical entity (NCE) accepted by the US FDA.
Wockhardt aims to launch Zaynich in the US in mid-2026.
This marks a significant milestone in Indian drug innovation.
- Who
- Wockhardt
- What
- Launched antibiotic Miqnaf in India and received US FDA acceptance for Zaynich
- When
- 2025 for Miqnaf, mid-2026 for Zaynich US launch
- Where
- India and the US
- Why
- Part of a long-term antibiotic drug discovery program
- Company
- Wockhardt
- Antibiotic Launched in India
- Miqnaf
- Antibiotic Accepted by US FDA
- Zaynich
- FDA Approval Type
- New Drug Application (NDA)
- US Launch Timeline
- Mid-2026